Biofrontera Inc. Selling, General and Administrative Expense
Biofrontera Inc. (BFRI) reported Selling, General and Administrative Expense of $9.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-13
- Biofrontera Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $9.63M, a 8.55% decline year-over-year.
- Biofrontera Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $10.99M, a 27.05% increase year-over-year.
- Biofrontera Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $8.52M, a 3.88% increase year-over-year.
- Biofrontera Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $10.05M, a 19.25% increase year-over-year.
- Biofrontera Inc. selling, general and administrative expense for fiscal 2025 was $37.75M, a 11.71% increase from fiscal 2024.
- Biofrontera Inc. selling, general and administrative expense for fiscal 2024 was $33.79M, a 13.30% decline from fiscal 2023.
- Biofrontera Inc. selling, general and administrative expense for fiscal 2023 was $38.98M, a 10.92% increase from fiscal 2022.
- Biofrontera Inc. selling, general and administrative expense for fiscal 2022 was $35.14M, a 3.77% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.63M 10-Q · filed 2026-08-13 | $20.62M 10-Q · filed 2026-08-13 | $29.14M derived: sum of 3 quarters · filed 2026-08-13 | $39.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $10.99M 10-Q · filed 2026-05-14 | $19.52M derived: sum of 2 quarters · filed 2026-05-14 | $29.56M derived: sum of 3 quarters · filed 2026-05-14 | $40.09M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $18.57M derived: sum of 2 quarters · filed 2026-03-19 | $29.10M derived: sum of 3 quarters · filed 2026-08-13 | $37.75M 10-K · filed 2026-03-19 |
| 2025-09-30 | $10.05M 10-Q · filed 2025-11-12 | $20.57M derived: sum of 2 quarters · filed 2026-08-13 | $29.23M 10-Q · filed 2025-11-12 | $37.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $10.53M 10-Q · filed 2026-08-13 | $19.18M 10-Q · filed 2026-08-13 | $27.39M derived: sum of 3 quarters · filed 2026-08-13 | $35.81M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $8.65M 10-Q · filed 2026-05-14 | $16.86M derived: sum of 2 quarters · filed 2026-05-14 | $25.28M derived: sum of 3 quarters · filed 2026-05-14 | $33.20M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $8.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $16.63M derived: sum of 2 quarters · filed 2026-03-19 | $24.54M derived: sum of 3 quarters · filed 2026-03-19 | $33.79M 10-K · filed 2026-03-19 |
| 2024-09-30 | $8.43M 10-Q · filed 2025-11-12 | $16.34M derived: sum of 2 quarters · filed 2025-11-12 | $25.59M 10-Q · filed 2025-11-12 | $34.69M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $7.92M 10-Q · filed 2025-08-13 | $17.16M 10-Q · filed 2025-08-13 | $26.27M derived: sum of 3 quarters · filed 2025-08-13 | $34.88M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $9.25M 10-Q · filed 2025-05-15 | $18.35M derived: sum of 2 quarters · filed 2025-05-15 | $26.97M derived: sum of 3 quarters · filed 2025-05-15 | $38.43M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $17.72M derived: sum of 2 quarters · filed 2024-03-15 | $29.18M derived: sum of 3 quarters · filed 2024-03-15 | $38.98M 10-K · filed 2024-03-15 |
| 2023-09-30 | $8.62M 10-Q · filed 2023-11-09 | $20.07M derived: sum of 2 quarters · filed 2023-11-09 | $29.87M 10-Q · filed 2023-11-09 | $39.96M derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-06-30 | $11.46M 10-Q · filed 2023-08-11 | $21.25M 10-Q · filed 2023-08-11 | $31.34M derived: sum of 3 quarters · filed 2024-03-15 | $39.11M derived: sum of 4 quarters · filed 2024-03-15 |
| 2023-03-31 | $9.80M 10-Q · filed 2023-05-12 | $19.89M derived: sum of 2 quarters · filed 2024-03-15 | $27.65M derived: sum of 3 quarters · filed 2024-03-15 | $37.32M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-12-31 | $10.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $17.85M derived: sum of 2 quarters · filed 2024-03-15 | $27.52M derived: sum of 3 quarters · filed 2024-03-15 | $35.14M 10-K · filed 2024-03-15 |
| 2022-09-30 | $7.76M 10-Q · filed 2023-11-09 | $17.43M derived: sum of 2 quarters · filed 2023-11-09 | $25.05M 10-Q · filed 2023-11-09 | $34.15M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $9.67M 10-Q · filed 2023-08-11 | $17.29M 10-Q · filed 2023-08-11 | $26.39M derived: sum of 3 quarters · filed 2023-08-11 | $43.48M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $7.62M 10-Q · filed 2023-05-12 | $16.72M derived: sum of 2 quarters · filed 2023-05-12 | $33.81M derived: sum of 3 quarters · filed 2023-05-12 | $39.36M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | $26.19M derived: sum of 2 quarters · filed 2023-03-13 | $31.74M derived: sum of 3 quarters · filed 2023-03-13 | $36.51M 10-K · filed 2023-03-13 |
| 2021-09-30 | $17.09M 10-Q · filed 2022-11-14 | $22.64M derived: sum of 2 quarters · filed 2022-11-14 | $27.41M 10-Q · filed 2022-11-14 | $31.55M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $5.55M 10-Q · filed 2022-08-12 | $10.31M 10-Q · filed 2022-08-12 | $14.46M derived: sum of 3 quarters · filed 2022-08-12 | $18.65M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $4.76M 10-Q · filed 2022-05-13 | $8.91M derived: sum of 2 quarters · filed 2022-05-13 | $13.10M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $4.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11 | $8.34M derived: sum of 2 quarters · filed 2022-04-11 | $17.71M 10-K · filed 2022-04-11 | |
| 2020-09-30 | $4.19M 10-Q · filed 2021-11-30 | $13.56M 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |